文献速递小儿麻醉心胸血管麻醉

平衡胶体是否减少小儿心脏手术围术期失血:双盲随机对照试验

Does a balanced colloid decrease perioperative blood loss in paediatric cardiac surgery: A double-blinded randomized controlled trial?
PubMed 文献 · Eur J Anaesthesiol · 2021-01-01

该双盲随机对照试验纳入88例29天至3岁行体外循环心脏手术的患儿,比较平衡电解质胶体与生理盐水胶体用于围术期液体治疗对失血的影响。结果显示两组术后第3天计算失血量无显著差异(生理盐水胶体19.9 vs 平衡胶体15.9 ml kg-1,P=0.409),出血相关次要结局、血制品暴露及凝血指标均无差异。

要点

  • 平衡胶体与生理盐水胶体在小儿心脏手术中围术期失血量无显著差异。
  • 两组血制品暴露、凝血指标及机械通气时间、ICU和住院时间均无差异。
  • 不能以平衡胶体替代生理盐水胶体来减少小儿心脏手术失血。

核心结论

  • 与生理盐水胶体相比,围术期使用平衡胶体并未减少小儿心脏手术的失血量或血制品暴露。

研究设计与样本

  • 双盲随机对照试验,2013至2016年单中心三级儿童医院,88例29天至3岁行体外循环心脏手术患儿,每组44例。

主要发现

  • 术后第3天计算失血量两组无显著差异:生理盐水胶体19.9(IQR 13.8至26.1)ml kg-1 vs 平衡胶体15.9(IQR 9.0至25.3)ml kg-1,P=0.409。
  • 出血相关次要结局、血制品暴露及凝血指标两组均无差异。
  • 机械通气时间、ICU停留时间和住院时间两组均无差异。

关键数值与推荐

  • 干预为6%羟乙基淀粉130/0.4分别溶于0.9% NaCl(生理盐水胶体)或等渗平衡电解质溶液(平衡胶体),用于体外循环预充及术中、术后48小时液体治疗。
  • 主要结局为术后第3天计算失血量。

临床怎么用

  • 小儿心脏手术围术期选择平衡胶体或生理盐水胶体对失血影响无差异,不应以减少失血为目的常规更换液体类型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Unbalanced fluid solutions cause metabolic acidosis and could be associated with impaired coagulation and increased blood loss. OBJECTIVE: To investigate whether the use of a balanced colloid compared with a saline colloid for peri-operative fluid therapy in children undergoing cardiac surgery is associated with decreased blood loss and exposure to blood products. DESIGN: Double-blinded randomised controlled trial. SETTING: Tertiary children's hospital from 2013 to 2016. PATIENTS: Children older than 29 days and younger than 3 years admitted for cardiac surgery with cardiopulmonary bypass (CPB). Exclusion criteria were emergency cardiac surgery, moribund (American Society of Anesthesiologists 5), Jehovah's witnesses, coagulopathy, renal failure, liver injury, intracranial haemorrhage and electrolyte disturbances. From the 128 patients eligible, 88 were included in the study. INTERVENTION: Random assignment of patients to either a saline colloid (6% hydroxyethyl starch 130/0.4 in 0.9% NaCl) or a balanced-electrolyte colloid (6% hydroxyethyl starch 130/0.4 in an isotonic solution) for CPB priming and intra- and postoperative fluid therapy during the first postoperative 48 h. MAIN OUTCOME MEASURE: The primary outcome measure was calculated blood loss until the third postoperative day (POD3). RESULTS: A total of 44 patients were included in each study arm. Calculated blood loss at POD3 was not significantly different between the groups (saline colloid 19.9 [IQR 13.8 to 26.1] ml kg-1 versus balanced colloid 15.9 [IQR 9.0 to 25.3 ml kg-1], P = 0.409). Secondary outcomes related to bleeding, exposure to blood products and coagulation were not different between groups. There was also no difference in length of mechanical ventilation, intensive care and hospital length of stay between groups. CONCLUSION: The use of a balanced colloid for peri-operative fluid therapy compared with a saline one is not associated with decreased blood loss or exposure to blood products. TRIAL REGISTRATION: EudraCT identifier: 2012-006034-17 and ClinicalTrial.gov identifier: NCT02584868.

来源:Eur J Anaesthesiol,查看原文。版权归原作者所有。

引用

  1. Willems A, De Groote F, Schmartz D, et al. Does a balanced colloid decrease perioperative blood loss in paediatric cardiac surgery: A double-blinded randomized controlled trial? Eur J Anaesthesiol. 2021. PMID: 33966019. doi:10.1097/EJA.0000000000001526

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。